A study by Astrup et al., comparing the efficacy of GLP-1 agonists versus orlistat in treating obesity, demonstrated that liraglutide 3 mg led to a 76% weight loss exceeding 5%, outperforming both the placebo (30%) or orlistat (44%). The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.